Webster Equity Partners to Acquire Lifecore Biomedical for $6.28 Per Share

Key Facts

1Lifecore Biomedical has agreed to be acquired by Webster Equity Partners in a cash deal valued at $6.28 per share.

2Shareholders will also receive Contingent Value Rights (CVRs) that could potentially increase total compensation to $9.67 per share.

3Craig-Hallum downgraded the stock to 'Hold' with a price target of $6.28 to align with the acquisition offer.

Lifecore Biomedical has agreed to be acquired by Webster Equity Partners in a cash deal valued at $6.28 per share. Financial Modeling Prep reported that shareholders will also receive Contingent Value Rights (CVRs) that could potentially increase total compensation to $9.67 per share upon meeting specific performance goals.

Craig-Hallum downgraded the stock to 'Hold' with a price target of $6.28 to align with the acquisition offer. LFCR closed at $4.20 on September 25, 2026, prior to the announcement of the deal which represents a premium over previous trading levels.